[{"id":"f1cfe322-7c0f-4270-b499-e5b443eefa43","acronym":"CARLOTTA01","url":"https://clinicaltrials.gov/study/NCT05836896","created_at":"2023-05-01T14:03:57.086Z","updated_at":"2024-07-02T16:35:18.546Z","phase":"Phase 1","brief_title":"A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","source_id_and_acronym":"NCT05836896 - CARLOTTA01","lead_sponsor":"Technische Universität Dresden","biomarkers":" CD31 • SLAMF7","pipe":" | ","alterations":" CD38 positive","tags":["CD31 • SLAMF7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDC-CAR-BCMA001"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-02-20"}]